Increasing mortality and morbidity associated with opioid analgesics has led to concerns about their misuse and abuse, even when obtained through a prescription. These concerns have been most pronounced in the United States, but limited data make it difficult to determine whether it is a problem in other countries. We investigated opioid analgesic misuse and abuse in participants from the Global Drug Survey 2015 resident in the United States (N 5 1334), United Kingdom (N 5 1199), France (N 5 1258), Germany (N 5 866), and Australia (N 5 1013) who had used at least 1 prescription opioid analgesic medication in the past year. We also investigated the relationship with polysubstance use, one of the most consistent predictors of problematic opioid analgesic use. Data included misuse and abuse of codeine, hydrocodone, oxycodone, and tramadol; ability to obtain a prescription; different sources for obtaining drugs; and past-year use of benzodiazepines and illicit drugs. In multilevel models, country of residence accounted for less than 3% of the variance in opioid analgesic misuse or abuse. Adjusting for country of residence and sociodemographic factors, use of illicit drugs and benzodiazepines was associated with 4-fold greater odds of misuse (odds ratio 4.36, 95% confidence interval 3.29-5.93) and 6-fold greater odds of abuse compared with not using either drug (odds ratio 6.49, 95% confidence interval 4.0-10.48), although the strength of the association with abuse varied by country. Misuse and abuse by those prescribed opioid analgesics seem to be a problem that is not limited to the United States and warrant attention on an international scale.
Introduction
Over the last decade, increasing mortality and morbidity associated with opioid analgesics has led to concerns about misuse and abuse of these drugs, even when obtained through prescription. This has been most pronounced in the United States where dispensed prescriptions increased from 47 million in 2006 to 60 million in 2013. 10 This was accompanied by increases in opioid-related overdose mortality and admission for treatment. 21 Policies designed to counter these trends have had some effect, with diversion, abuse, and attributable mortality reaching a plateau from 2011. 10 However, concerns have been raised that misuse and abuse of opioid analgesics are not limited to those who access them through nonclinical routes, and has not been adequately addressed in individuals using them for legitimate medical needs. 5, 21, 39 A recent review of opioid analgesic use in patients with chronic pain identified substantial levels of problematic use. 37 Three types of problematic use were defined using statements from the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials and Analgesic, Anesthetic, and Addiction Clinical Trials, Translations, Innovations, Opportunities, and Networks 26, 33 :
(1) Misuse: use contrary to the directed pattern of use, regardless of harm or adverse effects; (2) Abuse: intentional use for a nonmedical purpose; (3) Addiction: pattern of continued use with experience of, or demonstrated potential for, harm. The authors estimated misuse was documented in 21% to 29% of patients, and addiction in 8% to 12%. Abuse could not be estimated because of insufficient data, but in the one suitable study identified 8% of patients who met the abuse criteria. However, the authors noted that most studies reviewed were from the United States, and raised the question of whether problematic opioid analgesic use is "a problem that is somehow uniquely relevant to the US."
There is evidence of problematic opioid analgesic use outside the United States, particularly in Europe and Australia. Although heroin is the most frequently abused opioid in Europe, demand for treatment relating to problematic use of other opioids is increasing. 12 A 2012 review identified opioid analgesics as one of the most commonly misused medicines in Europe, although the authors also noted the limited available data. 8 A more recent study estimated the prevalence of prescription opioid abuse as 13.7 per 10,000 individuals for France, 11.0 per 10,000 for Germany, and 10.7 per Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article.
Using Global Drug Survey data from the United States, United Kingdom, France, Germany, and Australia, we investigated whether misuse and abuse of opioid analgesics obtained through prescription varied between countries. As polysubstance use involving illicit drugs or benzodiazepines is among the few consistent, strong predictors of problematic opioid analgesic use, 8, 31, 35 we also investigated whether the association between this predictor and misuse or abuse varied between countries.
Methods

Sample
Data were drawn from the 2015 Global Drug Survey (GDS), an annual online anonymous cross-sectional survey of licit and illicit drug use which ran from November 9, 2014 to January 3, 2015 (www.globaldrugsurvey.com). The GDS includes a core set of drug history and sociodemographic variables, with additional modules on specialist topics included or excluded each year. Starting with a universal drug screen, the web-based survey then adjusts to ensure only sections relevant to each persons' recent drug use experience are displayed. Further information on the range of topics covered is available at www.globaldrugsurvey. com/gds-surveys/survey-composition/. For the analyses presented, data were drawn from a specialist module on prescription drugs, and the sociodemographic and universal drug screen sections.
All participants confirmed they were aged $16 years and consented to analysis of the information they provided. Ethical approval was received from The Psychiatry, Nursing and Midwives Ethics Subcommittee at King's College London. The survey was translated into 10 languages and promoted in partnership with a range of media outlets including The Guardian, Zeit Online, la Repubblica, and Fairfax Media, and also distributed through Facebook, Twitter, social news website, reddit, and drug discussion forums. There are no exclusion criteria except being younger than the age of 16 years and thus it was open to any individual who wished to complete it. The 2015 GDS was available in English, Danish, Flemish, French, German, Greek, Hungarian, Italian, Portuguese, Spanish, and Slovenian and distributed through media partners in Australia, Belgium, Denmark, France, Germany, Greece, Hungary, Ireland, Mexico, the Netherlands, New Zealand, Poland, Portugal, Slovenia, Spain, Switzerland, the United Kingdom, and the United States. However, as this was an online survey and it was advertised through social media, responses were also received from individuals residing in other countries. Global Drug Survey, therefore, recruits a nonprobability sample and is not designed to determine the prevalence of drug behaviours in the general population. GDS is, however, an efficient way of gaining in-depth understanding of stigmatized behaviors that may not be well captured in more representative surveys. Other publications provide further details on the utility, design, and limitations of the Global Drug Survey. 3, 6, 25, 40 In total, the 2015 GDS received responses from over 100,000 participants from 175 countries, with 31 countries contributing 100 or more responses. Our original intention was to analyse data from the United States, Australia, and the 5 European countries examined by Shei et al. 32 (United Kingdom, France, Germany, Spain, and Italy). However, we could only include countries with enough overall participants to ensure a sufficient sample of prescription opioid users for the multilevel analyses (described below). Unfortunately, less than 1000 responses were received from participants resident in Italy and Spain so we could not include these countries in the analyses. Thus, the analysis sample was defined as GDS on participants from Australia, France, Germany, the United Kingdom, and the United States who had used prescription codeine, hydrocodone, oxycodone, or tramadol in the past 12 months. The relative frequency of prescribing of these opioid analgesics differs between countries: codeine and tramadol are more commonly prescribed in the United Kingdom, France, and Germany, 1, 15, 30 whereas oxycodone and hydrocodone are more commonly prescribed in the United States. 38 In Australia, codeine is prescribed most frequently, followed by tramadol and oxycodone which are prescribed at similar frequencies. Information was collected on sex, age, and highest educational qualification (high school, college diploma, undergraduate, and postgraduate).
Drug use
Participants were asked "Have you used any of the following drugs in the last year?" and presented with a list of illicit drugs and licit drugs (including opioid analgesics and benzodiazepines). The following questions were revealed dynamically for each opioid analgesic for which they endorsed past-year use.
Methods of access
Participants were asked "Which of the following methods have you used to obtain it [specific medication]?" with the following options: Prescribed to you; Given to you by a friend; Bought by you from a dealer; Bought by you on the internet (multiple selections possible).
Ease of access to a prescription
Participants were asked "How easy would it be for you get it [drug] prescribed to you within the next 7 days?" selecting one option from: Very easy; Easy; Possible; Difficult; Very difficult. Responses were collapsed into a binary variable indicating "Very easy" or "Easy" responses vs other responses.
Opioid analgesic misuse and abuse
Misuse and abuse were defined following Vowles et al. 37 In our data, misuse was coded if participants endorsed one or more of the following responses to "If it [drug] was prescribed to you in the last 12 months have you found yourself…": (1) taking more than was prescribed; (2) trying to get hold of extra medication; (3) being unable cut down or stop using it; (4) feeling physically or emotionally unwell when using less or stopping use; (5) ever overdosed.
Abuse was coded if participants endorsed one or more of the following responses to the same question: (1) mixing it with other drugs to enhance the drug effect; (2) mixing it with alcohol to enhance the drug effect.
Abuse was also coded if participants endorsed the option "getting high" when responding to the question "In the last year have you taken this medication to achieve these desirable objectives…."
Misuse and abuse variables were derived separately for each opioid analgesic, but as some participants endorsed the use of more than 1 opioid analgesic, these data were also combined to create 2 variables indicating misuse of at least 1 opioid analgesic and abuse of at least 1 opioid analgesic.
Polysubstance use
Using the screening question "Have you used any of the following drugs in the past year?," we identified participants who endorsed use of benzodiazepines (with or without a prescription) or the following illicit drugs: cannabis (hydroponic, herbal, resin, or oil), ecstasy (pills or powder), cocaine, crack, amphetamine, methamphetamine, mephedrone, or heroin. For descriptive purposes, we used these data to create a categorical variable indicating the following mutually exclusive patterns of substance use: no use of illicit drugs or benzodiazepines in the past year; use of one or more illicit drugs only; use of benzodiazepines only; use of one or more illicit drugs and benzodiazepines (combined use). For analytical purposes, we created 2 binary variables, one indicating use of illicit drugs in the past year and the other indicating use of benzodiazepines in the past year.
Statistical analysis
Sample characteristics were summarised using standard descriptive statistics. Multivariable analyses were conducted using multilevel (ie, mixed effects) binary logistic regression models to allow for clustering of participants within countries, and estimation of the variability in misuse and abuse due to country of residence. These models were used to investigate the association between polysubstance use and (1) misuse of at least 1 prescription opioid analgesic; (2) abuse of at least 1 prescription opioid analgesic. Age, sex, education level, and employment status were included as covariates.
Models included a random country-level intercept to allow for between-country variation in risk of opioid analgesic misuse and abuse. The effect of country of residence was quantified using the intraclass correlation and median odds ratio (OR). 23 Illicit drug use and benzodiazepine use were initially modelled as fixed effects with an interaction term; random slope models were then fitted to evaluate whether the associations between misuse or abuse and illicit drug use and benzodiazepine use varied by country of residence. The models provide OR estimates for the association between polysubstance use and misuse or abuse, holding country of residence constant.
14, 16 The covariates age, sex, education level, and employment were included as fixed effects. Models were fitted via maximum likelihood with difference in model fit evaluated using likelihood ratio x 2 tests. As the alternative hypotheses regarding variances are technically one sided, halving the P value for these tests has been suggested 34 ; we report the standard P values but consider this modification when interpreting results. Analyses were conducted in R version 3.3.1 (Bug in Your Hair) 28 using the lme4 package for multilevel models, with 95% confidence intervals (CIs) for the final model parameter estimates obtained using bootstrapping with 4000 replicates per model. 4 
Results
Sample description
The analysis sample consisted of 5670 participants who had used codeine, hydrocodone, oxycodone, or tramadol in the past 12 months and had obtained it through a prescription ( Table 1) . Overall, 45.8% of the samples were women with an average age of 33.2 years (SD 13.8 years). Participants were relatively evenly distributed across the education categories: 24.9% reported high school as their highest qualification; 22.2% reported a college diploma; 28.7% reported an undergraduate degree; and 22.6% reported a postgraduate degree. Almost two-thirds (64.1%) were employed. The analysis sample differs from the total sample of GDS participants from the 5 countries in that the full sample has a lower percentage of women (37%), lower average age (30.0 years), fewer participants with a postgraduate qualification (14.9%), and a lower level of employment (60.7%).
The analysis sample included similar numbers of participants from each of the 5 countries, although there were slightly fewer from Germany. Use of particular opioid analgesics differed by country of residence, as expected given regional differences in prescribing practices. Codeine was the most frequently used drug by participants resident in Australia (91.2%), France (90.6%), Germany (77.7%), and the United Kingdom (92.8%), whereas hydrocodone was most commonly used by US participants (63.9%). Overall, 45.4% of the sample had not used benzodiazepines or illicit drugs in the past year. Past-year illicit drug use was reported by a further 42.3%, with 4.4% having used only benzodiazepines in the past year, and 7.9% endorsing use of both benzodiazepines and illicit drugs. Of those who had used illicit drugs in the past year more than half (57.0%) had only used cannabis, with ecstasy (12.2%) and cocaine (10.0%) the next most frequently used single drugs. Only 2% (N 5 58) of illicit drug users had used heroin in the past year. Of those who had used benzodiazepines in the past year, 61.7% reported obtaining them through prescription.
Access to opioid analgesics
Obtaining a prescription for these opioid analgesics within 7 days was perceived as being easier for codeine (39.4% reported it would be "very easy" or "easy") and tramadol (46.4%), compared to hydrocodone (18.4%) and oxycodone (25.1%). Obtaining any of these opioid analgesics without a prescription, from a dealer or the internet, was very uncommon (Fig. 1) . Only approximately 1% of codeine and tramadol users reported obtaining these drugs from a dealer or the internet. For hydrocodone and oxycodone, the percentage of participants who also reported obtaining the drug from a dealer was higher (7.0% and 5.7% respectively), but the percentage buying these drugs through the internet was less than 1%. Being given these drugs by friends was a more common route for obtaining them without a prescription (reported by 6.7% to 23.2% of participants, depending on drug).
Level of misuse and abuse of opioid analgesics
Between 8% and 22% of participants who had not used any illicit drugs or benzodiazepines in the past year reported misuse or abuse of codeine, hydrocodone, oxycodone, or tramadol ( Table 2) . Overall, compared with those who had not used any other substances, approximately twice as many participants who had used illicit drugs only, or benzodiazepines only, reported misuse of any opioid analgesic (26.8% and 33.5%, respectively, compared with 14.7%). Three times as many participants who engaged in polysubstance use reported misuse (45.7%). Participants who only used illicit drugs, or only used benzodiazepines, were approximately 3 times as likely to report abuse of opioid analgesics compared with those who used no other substances (23.9% and 27.8%, respectively, compared with 8.8%). Almost 5 times as many participants who endorsed polysubstance use reported abuse of opioid analgesics (43.7%). The percentage of participants reporting misuse and abuse differed by country of residence; Australian participants were the least likely to report misuse and abuse (17.0% and 12.5%, respectively), whereas participants from the United States were most likely (28.2% and 27.7%, respectively). Similar percentages of participants from France and the United Kingdom reported misuse (21.5% and 21.0%, respectively) and abuse (15.6% and 16.6%, respectively). German participants reported a level of misuse similar to participants from the United States (27.5%), but were less likely to report abuse (20%).
Association between polysubstance use and misuse or abuse of prescription opioid medications
We first fitted "empty" multilevel models to investigate how much variability in misuse and abuse of opioid analgesics could be explained by participant country of residence. 24 For both models, likelihood ratio tests comparing fixed effects and random intercept models indicated that there was significance variance explained by the between-country effect on misuse (x 2 1 5 34.98, P , 0.0001) and abuse (x 2 1 5 73.53, P , 0.0001). However, the intraclass correlations and median ORs for both models were small. The percentage of variance in misuse explained by country of residence was only 1.5% and the median OR was 1.12, whereas the percentage of variance in abuse explained was 2.8% and the median OR was 1.34.
For the opioid analgesic misuse model, allowing the effects of illicit drug use and benzodiazepine use to vary by country of residence did not significantly improve model fit (x 2 5 5 8.53, P 5 0.13), and they were, therefore, included as fixed effects in the full multivariable model. Based on the full multivariable model ( Table 3) , use of both illicit drugs and benzodiazepines was associated with over 4-fold greater odds of opioid analgesic misuse compared with not using any additional substances Allowing the effects of illicit drug use and benzodiazepine use to vary by country of residence did significantly improve the fit of the model for opioid analgesic abuse (x 2 5 5 13.26, P 5 0.02). The effect of illicit drug use on abuse varied considerably more between country of residence than the effect of benzodiazepine use ( Table 3) . Covariance with the intercept was negative for both illicit drug use and benzodiazepine use, suggesting that the association of polysubstance use with abuse is weaker in countries with higher levels of abuse. The fixed effects estimates for the relationship between polysubstance use and opioid analgesic abuse were stronger than those for misuse, but displayed the same pattern. The odds of opioid analgesic abuse were highest for participants using both illicit drugs and benzodiazepines compared with those not using any additional substances (OR 6.49, 95% CI 4.0-10.48), over 4-fold higher for those using benzodiazepines only (OR 4.79, 95% CI 2.70-8.95), and over 2-fold higher for those using only illicit drugs (OR 2.46, 95% CI 1.75-3.60).
Discussion
In this sample of individuals from the United States, United Kingdom, France, Germany, and Australia who had used opioid medications obtained through prescription in the past year, 1 in 4 individuals reported misuse of any opioid analgesics, and approximately 1 in 5 individuals reported abuse. Although these data come from a nonprobability sample, this level of opioid medication misuse is similar to that obtained from a recent systematic review of misuse, abuse, and addiction in patients with chronic pain, 37 and represents one of the few available estimates of level of abuse of these drugs. Misuse and abuse Table 2 Levels of opioid analgesic misuse and abuse by polysubstance use. Percentages are shown for each opioid analgesic and for misuse or abuse of at least 1. Table 3 Estimates from multilevel models of associations between opioid analgesic misuse and abuse, polysubstance use, and sociodemographic characteristics. differed between those who had and had not used illicit drugs or benzodiazepines in the past year; approximately 1 in 7 nonusers reported misuse and 1 in 11 reported abuse, compared with approximately 1 in 3 users reporting misuse or abuse. The multilevel models fitted indicated that country of residence only accounted for a small proportion of the variance in opioid analgesic misuse and abuse. Holding the effect of country of residence constant and adjusting for sociodemographic factors, combined use of illicit drugs and benzodiazepines was associated with 4-fold greater odds of opioid analgesic misuse and 6-fold greater odds of abuse compared with not using either drug. There were no significant between-country differences in the effect of either illicit drug use or benzodiazepine use on misuse. However, the association between both types of polysubstance use and opioid analgesic abuse varied by country of residence, with this being more pronounced for illicit drug use. Thus, although these results provide limited support for the idea that misuse and abuse of these opioid analgesics is a phenomenon specific to the United States, we did find evidence that the relationship between some risk factors and opioid analgesic abuse may differ between countries.
The importance of benzodiazepine use in the context of problematic use of opioid analgesics is perhaps unsurprising given that the combined use of these drugs is well documented, 20 and benzodiazepine use is a risk factor for opioid misuse 8 and overdose. 19, 41 As those using both opioids and benzodiazepines are at an increased risk of fatal overdose, this finding highlights the need for clinicians to be vigilant in identifying risk behaviours in those in receipt of both medication classes. Despite most clinical guidelines cautioning against concomitant prescription, there may be genuine indications such as managing coexistent anxiety or augmenting analgesic effects. 17 In our sample of prescription opioid users, just over 60% of benzodiazepine users reported also obtaining this drug through a prescription. However, prescription opioids and benzodiazepines are 2 of the drugs most commonly obtained through "doctor shopping," 19, 22 so it is possible that in many cases a prescription for one drug was obtained without the clinician knowing the patient already held a prescription for the other. Regional differences in family doctor registration and prescription drug monitoring programmes, which can help prevent doctor shopping, could account for some of the between-country variation we observed in the association between polysubstance use and prescription opioid abuse. 36 The interplay between illicit drugs, benzodiazepines, and opioid analgesics is less well characterised. As only 2% of those who had used illicit drugs in the past year were heroin users, it is unlikely that the results were driven by use of opioid analgesics as a substitute for heroin. For 57% of participants using both illicit drugs and opioid analgesics, cannabis was the only illicit drug they had used in the past year. Cannabis use has been identified as a risk factor for opioid analgesic misuse in patients with chronic pain, 29 and previous research identified a pattern of polysubstance use involving cannabis and both opioid analgesics and benzodiazepines which was associated with increased risk of mental illness, another risk factor for opioid misuse and abuse. 9, 11, 25, 31 However, efforts to develop risk prediction models for problematic opioid analgesic use have generally grouped all substance use disorders together. 9, 11 More research is needed to investigate the interaction between different illicit drugs and benzodiazepines to better understand how use of these drugs increases risk of problematic opioid analgesic use.
One limitation of these results is that we used data on pastyear drug use, which is not necessarily the same as simultaneous use within a short time frame (eg, 24 hours), although Quek et al. 27 found that most people reporting use of multiple drugs in the past year also reported simultaneous use of those drugs. The other main limitation is that these data were collected through an anonymous online survey using a nonprobability sampling strategy. It is not possible to estimate response rates for this type of sampling strategy and it cannot be considered to provide a representative sample of individuals from the countries included, so the results should not be generalised to the broader populations from which they are drawn. Participants in this type of study are likely to be younger, male, urban dwelling, endorse use of illicit drugs, and have completed more years of formal education than participants from a representative sample. 2 However, although the recruitment strategy may not provide a representative sample, the fact that it was anonymous and did not involve a participant's clinical care provider may mean that people were more likely to disclose both misuse and abuse of opioid analgesics, and use of illicit drugs. In addition, this data set provided a large sample of individuals who had obtained opioid analgesics through a prescription across several countries. Given the noted scarcity of data on problematic use of opioid analgesics from outside the United States, 8, 32, 37 these data are useful for exploring this phenomenon and generating new research questions. Regardless, the findings presented here should be investigated further in representative samples from the United States, United Kingdom, France, Germany, and Australia.
In conclusion, levels of opioid analgesic misuse and abuse seem to be higher in those who engage in polysubstance use involving illicit drugs or benzodiazepines, but there are substantial numbers of individuals who are not polysubstance users and engage in misuse or abuse. Policies and interventions have been developed on the assumption that there are 2 distinct populations of people, one that uses only medication prescribed to them and are compliant with dosing instructions, and another group who obtain prescription opioids through nonclinical routes, use other licit or illicit drugs, and engage in misuse and abuse. This distinction does not accurately reflect the reality of prescription opioid use, and highlights the importance of universal approaches to patient education, prescription, and patient monitoring. Although doctors remain the major source for these drugs, they will need to be targeted and engaged as the pivotal sites for change. Differences between the United States and other developed countries in relation to health care regulatory systems, patient expectations, and direct-to-consumer advertising have contributed to the substantially greater magnitude of problematic opioid analgesic use in the United States. 13, 36, 38 However, the issue of misuse and abuse amongst those who are prescribed opioid analgesics seems to be a problem that warrants attention on an international scale. 
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